SI0779810T1 - Use of ketoconazole and related substances in medicaments for treatment of type ii diabetes - Google Patents

Use of ketoconazole and related substances in medicaments for treatment of type ii diabetes

Info

Publication number
SI0779810T1
SI0779810T1 SI9430454T SI9430454T SI0779810T1 SI 0779810 T1 SI0779810 T1 SI 0779810T1 SI 9430454 T SI9430454 T SI 9430454T SI 9430454 T SI9430454 T SI 9430454T SI 0779810 T1 SI0779810 T1 SI 0779810T1
Authority
SI
Slovenia
Prior art keywords
ketoconazole
diabetes
medicaments
type
treatment
Prior art date
Application number
SI9430454T
Other languages
English (en)
Slovenian (sl)
Inventor
Per Marin
Original Assignee
Cortendo Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cortendo Ab filed Critical Cortendo Ab
Publication of SI0779810T1 publication Critical patent/SI0779810T1/xx

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50Pyridazines; Hydrogenated pyridazines
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/56Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/06Antihyperlipidemics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00Drugs for disorders of the endocrine system
    • A61P5/48Drugs for disorders of the endocrine system of the pancreatic hormones
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/12Antihypertensives
    • BPERFORMING OPERATIONS; TRANSPORTING
    • B65CONVEYING; PACKING; STORING; HANDLING THIN OR FILAMENTARY MATERIAL
    • B65BMACHINES, APPARATUS OR DEVICES FOR, OR METHODS OF, PACKAGING ARTICLES OR MATERIALS; UNPACKING
    • B65B1/00Packaging fluent solid material, e.g. powders, granular or loose fibrous material, loose masses of small articles, in individual containers or receptacles, e.g. bags, sacks, boxes, cartons, cans, or jars
    • B65B1/04Methods of, or means for, filling the material into the containers or receptacles
    • B65B1/08Methods of, or means for, filling the material into the containers or receptacles by vibratory feeders

Landscapes

  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Emergency Medicine (AREA)
  • Mechanical Engineering (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Steroid Compounds (AREA)
SI9430454T 1994-08-09 1994-08-09 Use of ketoconazole and related substances in medicaments for treatment of type ii diabetes SI0779810T1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/SE1994/000729 WO1996004912A1 (en) 1994-08-09 1994-08-09 Use of ketoconazole and related substances in medicaments for treatment of type ii diabetes

Publications (1)

Publication Number Publication Date
SI0779810T1 true SI0779810T1 (en) 2003-12-31

Family

ID=20393155

Family Applications (1)

Application Number Title Priority Date Filing Date
SI9430454T SI0779810T1 (en) 1994-08-09 1994-08-09 Use of ketoconazole and related substances in medicaments for treatment of type ii diabetes

Country Status (14)

Country Link
US (2) US5849740A (xx)
EP (2) EP0779810B8 (xx)
JP (1) JP3825469B2 (xx)
KR (1) KR100422162B1 (xx)
AT (1) ATE244009T1 (xx)
CA (1) CA2196174C (xx)
CZ (1) CZ285290B6 (xx)
DE (1) DE69432905T2 (xx)
DK (1) DK0779810T3 (xx)
ES (1) ES2202326T3 (xx)
NO (1) NO314616B1 (xx)
PT (1) PT779810E (xx)
SI (1) SI0779810T1 (xx)
WO (1) WO1996004912A1 (xx)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1996004912A1 (en) * 1994-08-09 1996-02-22 Metabolic Syndrome I Gbg Ab Use of ketoconazole and related substances in medicaments for treatment of type ii diabetes
US6642236B1 (en) * 1998-12-14 2003-11-04 Cortendo Ab Methods for prophylactic treatment of cardiovascular disease with inhibitor of cortisol synthesis
SE9700642D0 (sv) 1997-02-24 1997-02-24 Kronvall Stefan Med Ab Medel och sätt för förebyggande och behandling av det metabola syndromet
GB0001449D0 (en) * 2000-01-21 2000-03-08 Cortendo Ab Compositions
SE0001899D0 (sv) 2000-05-22 2000-05-22 Pharmacia & Upjohn Ab New compounds
GB0118300D0 (en) * 2001-07-26 2001-09-19 Cortendo Ab Formulations
AU2002365122A1 (en) * 2001-08-23 2003-07-15 New England Biolabs, Inc. A method for engineering strand-specific, sequence-specific, dna-nicking enzymes
US7094792B2 (en) 2001-11-22 2006-08-22 Biovitrum Ab Inhibitors of 11-beta-hydroxy steroid dehydrogenase type 1
US9655865B2 (en) 2002-07-29 2017-05-23 Veroscience, Llc Therapeutic treatment for metabolic syndrome, type 2 diabetes, obesity, or prediabetes
US20080200453A1 (en) 2002-07-29 2008-08-21 Cincotta Anthony H Methods of treating metabolic syndrome using dopamine receptor agonists
US20040220190A1 (en) * 2002-07-29 2004-11-04 Cincotta Anthony H. Methods of treating metabolic syndrome using dopamine receptor agonists
US20040081678A1 (en) * 2002-08-09 2004-04-29 Anthony Cincotta Therapeutic process for the treatment of obesity and associated metabolic disorders
US8821915B2 (en) 2002-08-09 2014-09-02 Veroscience, Llc Therapeutic process for the treatment of the metabolic syndrome and associated metabolic disorders
EP2053409A1 (en) 2003-11-20 2009-04-29 F. Hoffmann-La Roche Ag Specific markers for metabolic syndrome
US20050215558A1 (en) * 2004-03-25 2005-09-29 Cincotta Anthony H Methods of identifying responders to dopamine agonist therapy
US8137994B2 (en) * 2004-03-25 2012-03-20 Veroscience Llc Methods of identifying responders to dopamine agonist therapy and treating metabolic conditions thereof
US8137993B2 (en) * 2004-03-25 2012-03-20 Veroscience Llc Methods of identifying responders to dopamine agonist therapy and treating metabolic conditions thereof
MX2007008331A (es) * 2005-01-10 2008-01-14 Cortendo Invest Ab Publ Metodos y composiciones para el tratamiento de diabetes, sindrome metabolico y otras condiciones.
EP1976526A2 (en) * 2006-01-10 2008-10-08 Diobex, Inc. Methods and compositions for treating prostate cancer
JP2006206605A (ja) * 2006-03-29 2006-08-10 Metabolic Syndrome I Goeteborg Ab 代謝性症候群の治療薬
EP1886695A1 (en) * 2006-06-27 2008-02-13 Speedel Experimenta AG Pharmaceutical combination of an aldosterone synthase inhibitor and a glucocorticoid receptor antagonist or a cortisol synthesis inhibitor or a corticotropin releasing factor antagonist
BRPI0719835A2 (pt) * 2006-10-02 2014-05-06 Cortendo Invest Ab Enantiômero de cetoconazol em humanos
US9352025B2 (en) 2009-06-05 2016-05-31 Veroscience Llc Combination of dopamine agonists plus first phase insulin secretagogues for the treatment of metabolic disorders

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5432176A (en) * 1988-11-29 1995-07-11 The John Hopkins University Method of retarding the progression of chronic renal failure
US5175144A (en) * 1988-11-29 1992-12-29 The Johns Hopkins University Method of retarding the progression of chronic renal failure
WO1996004912A1 (en) * 1994-08-09 1996-02-22 Metabolic Syndrome I Gbg Ab Use of ketoconazole and related substances in medicaments for treatment of type ii diabetes
US5591736A (en) * 1995-07-03 1997-01-07 The Johns Hopkins University Method of retarding the progression of chronic renal failure

Also Published As

Publication number Publication date
ES2202326T3 (es) 2004-04-01
DE69432905T2 (de) 2004-05-27
NO970567L (no) 1997-02-07
US6166017A (en) 2000-12-26
EP0779810B8 (en) 2003-09-17
CZ285290B6 (cs) 1999-06-16
JPH10510241A (ja) 1998-10-06
AU695011B2 (en) 1998-08-06
DK0779810T3 (da) 2003-10-20
WO1996004912A1 (en) 1996-02-22
KR100422162B1 (ko) 2004-07-07
CZ36097A3 (en) 1997-06-11
EP1360960A1 (en) 2003-11-12
US5849740A (en) 1998-12-15
ATE244009T1 (de) 2003-07-15
EP0779810B1 (en) 2003-07-02
JP3825469B2 (ja) 2006-09-27
DE69432905D1 (de) 2003-08-07
CA2196174A1 (en) 1996-02-22
AU7711894A (en) 1996-03-07
NO314616B1 (no) 2003-04-22
KR970704440A (ko) 1997-09-06
EP0779810A1 (en) 1997-06-25
PT779810E (pt) 2003-11-28
NO970567D0 (no) 1997-02-07
CA2196174C (en) 2005-03-01

Similar Documents

Publication Publication Date Title
SI0779810T1 (en) Use of ketoconazole and related substances in medicaments for treatment of type ii diabetes
IL135712A (en) Use of recombinant activated protein c in the manufacture of medicaments for treating or preventing acquired hypercoagulable states associated with sepsis
ATE186460T1 (de) Methode zur verhinderung von restenosierung nach rekanalisierung von körpergefässen
KR970706002A (ko) 남성의 상대적 안드로겐 결핍증 치료를 위한 약제의 제조에 있어서 아로마타제 억제제의 용도(Use of Aromatase Inhibitors in the Preparation of a Drug for Treating a Relative Androgen Deficiency in Men)
SE9802080D0 (sv) Pharmaceutical composition for the treatment of functional dyspepsia and/or irritable bowel syndrome and new use of substances therein
IL131801A0 (en) Use of thiazolidinedione derivatives in the treatment of polycystic ovary syndrome and gestational diabetes
MXPA01006511A (es) Combinacion de inhibidores de fb-pasa y sensibilizadores de insulina para el tratamiento de diabetes.
AU2003224742A1 (en) Method of administering buprenorphine to treat depression
SE9201573D0 (sv) Use of igf-1
ZA200110408B (en) Methods for treating diabetes.
WO2004087076A3 (en) Methods for inhibiting adipogenesis and for treating type 2 diabetes
IL133907A0 (en) Treatment of diabetes with thiazolidinedione, insulin secretagogue and alpha glucocidase inhibitor
PL334498A1 (en) Application of pramiprexole in treating the restless legs syndrome
IL130500A0 (en) Use of comt inhibitors for the manufacture of a medicament for the prevention of diabetic vascular dysfunctions
MX9707939A (es) Uso de antagonistas del factor inhibidor de la leucemia y la endotelina.
Barry et al. The effects of recombinant human growth hormone on cardiopulmonary function in elective abdominal aortic aneurysm repair
ES8500951A1 (es) Un procedimiento para preparar 6-metil-tio-espiro-ckroman-4,4' imidazolin-2',5'-diona.
UA32255A (uk) Спосіб лікування цукрового діабету
AU2003230830A8 (en) Treatment of type 1 diabetes before and after expression of predisposition markers
AU3268497A (en) Use of lofexidine in the manufacture of a medicament for treating attention deficit hyperactive disorder
UA29332A (uk) Спосіб лікування хронічного неспецифічного простатиту
NZ273710A (en) use of ketoconazole or a derivative which is a cortisol synthesis inhibitor in medicaments for treatment of type II diabetes
Kaido et al. Temporal profile of gene induction after venous ischemia accompanied by spreading depression as compared to spreading depression alone
陈荣钟 TREATMENT OF APOPLECTIC HEMIPLEGIA BY DIGITAL ACUPOINT PRESSURE-A Report of 42 Cases
AU695011C (en) Use of ketoconazole and related substances in medicaments for treatment of type II diabetes